SCHEMBL4772393

SCHEMBL4772393

OCc1ccnc(-c2ccc(Cl)cc2)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RECQL P46063 1/20 0.56
MAP4K4 O95819 2/20 0.49
NOTUM Q6P988 3/20 0.47
LOXL2 Q9Y4K0 2/20 0.46
CYP2C9 P11712 2/20 0.45
NR4A2 P43354 1/20 0.45
KCNH2 Q12809 1/20 0.45
MEN1 O00255 1/20 0.44
MAPT P10636 1/20 0.44
KMT2A Q03164 1/20 0.44
KMO O15229 2/20 0.42
CNR1 P21554 1/20 0.42
KRAS P01116 2/20 0.41
TGFBR1 P36897 1/20 0.40
MAPKAPK2 P49137 1/20 0.38
LMNA P02545 1/20 0.38
CYP1A2 P05177 1/20 0.38
GAA P10253 1/20 0.38
CYP2C19 P33261 1/20 0.38
PIM1 P11309 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4128508 0.84 MAP4K4 (0.46) MAP4K4NOTUMLOXL2CYP2C9MEN1
SCHEMBL4423076 0.83 KMO (0.56) RECQLLOXL2MAPTKMOKRAS
SCHEMBL220484 0.83 NR4A2 (0.69) CYP2C9NR4A2KCNH2MAPT
SCHEMBL27802351 0.82 NOS3 (0.47) MAP4K4LOXL2CYP2C9MEN1MAPT
SCHEMBL18233498 0.82 LOXL2 (0.62) MAP4K4NOTUMLOXL2MEN1MAPT
SCHEMBL21376947 0.82 MAP4K4 (0.45) MAP4K4NOTUMLOXL2CYP2C9MEN1
SCHEMBL4492835 0.82 RECQL (0.47) RECQLLOXL2MEN1KMT2AKRAS
SCHEMBL4772524 0.82 LOXL2 (0.50) RECQLNOTUMLOXL2
SCHEMBL14310545 0.82 LOXL2 (0.50) RECQLLOXL2MEN1MAPTKMT2A
SCHEMBL4764104 0.82 RECQL (0.47) RECQLLOXL2MEN1KMT2AKRAS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1400513-B1 UNSYMMETRICAL CYCLIC DIAMINE COMPOUND KOWA CO (JP) 2008-01-09 EP disclosed
EP-1000040-B1 IL-5 INHIBITING 6-AZAURACIL DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2007-06-13 EP disclosed
US-20050090495-A1 Novel IL-5 inhibiting 6-azauracil derivatives for marking and identifying receptors and imaging organs LACRAMPE JEAN FERNAND ARMAND (FR) 2005-04-28 US disclosed
US-6867207-B2 IL-5 inhibiting 6-azauracil derivatives JANSSEN PHARMACEUTICA N.V. (BE) 2005-03-15 US disclosed
US-20040167333-A1 Novel IL-5 inhibiting 6-azauracil derivatives for marking and identifying receptors and imaging organs LACRAMPE JEAN FERNAND ARMAND (FR) 2004-08-26 US disclosed
EP-1400513-A1 UNSYMMETRICAL CYCLIC DIAMINE COMPOUND Kowa Co., Ltd. (JP) 2004-03-24 EP disclosed
US-6552188-B2 Inhibit cell adhesion and cell infiltration; useful treating asthma, allergies, rheumatic diseases, arteriosclerosis, and inflammation; 2-(3,4,5-trimethoxyphenyl),4-((4-substituted piperazin-1-yl)methyl)pyridine compounds KOWA CO., LTD. (JP) 2003-04-22 US disclosed
US-20030022887-A1 Unsymmetrical cyclic diamine compound KOWA CO., LTD. (JP) 2003-01-30 US disclosed
US-20020072603-A1 Novel IL-5 inhibiting 6-azauracil derivatives LACRAMPE JEAN FERNAND ARMAND (FR) 2002-06-13 US disclosed
EP-1000040-A1 IL-5 INHIBITING 6-AZAURACIL DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 2000-05-17 EP disclosed
WO-1999002505-A1 IL-5 INHIBITING 6-AZAURACIL DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 1999-01-21 WO disclosed
US-4043790-A 2-OR 4-SUBSTITUTED PYRIDINE METHANE OR PYRIDINE METHANOL, NONHERBICIDAL ELI LILLY AND COMPANY (US) 1977-08-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040167333-A1 Novel IL-5 inhibiting 6-azauracil derivatives for marking and identifying receptors and imaging organs IL6ST, CXCR5, ALOX5 RECQL 4128/4885MAP4K4 4362/4885NOTUM 3849/4885
US-20050090495-A1 Novel IL-5 inhibiting 6-azauracil derivatives for marking and identifying receptors and imaging organs CXCR5, HCAR3, IL6ST RECQL 3489/4885MAP4K4 4527/4885NOTUM 4155/4885
US-20030022887-A1 Unsymmetrical cyclic diamine compound H1-0, DDAH1, AOC1 RECQL 1199/4885MAP4K4 2386/4885NOTUM 488/4885
US-20020072603-A1 Novel IL-5 inhibiting 6-azauracil derivatives IL6ST, ALOX5, IL5 RECQL 2542/4885MAP4K4 4504/4885NOTUM 2885/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.